Neurocrine Biosciences News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

15.05.23	Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Long-Term Improvements and Psychiatric Stability in Patients With Tardive Dyskinesia and Schizophrenia or Schizoaffective D... (PR Newswire)
12.05.23	Neurocrine Biosciences Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023 (PR Newswire)
03.05.23	Neurocrine Biosciences Inc Q1 Earnings Summary (RTTNews)
02.05.23	Neurocrine Biosciences to Present at the Bank of America Securities 2023 Healthcare Conference (PR Newswire)
01.05.23	Neurocrine Biosciences Supports the Mental Health Community During Tardive Dyskinesia Awareness Week (PR Newswire)
12.04.23	Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2023 Financial Results (PR Newswire)
21.03.23	Neurocrine Biosciences to Present at the Stifel 2023 CNS Days (PR Newswire)
09.03.23	Neurocrine Biosciences Announces Results from the Real-World RE-KINECT™ Study Published in the Journal of Patient-Reported Outcomes Demonstrating the Effects of Possible Tardive Dyskinesia (TD) on... (PR Newswire)
09.03.23	Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsule Contents via Soft Foods or Feeding Tube at AMDA - PALTC 2023 Annual Conference (PR Newswire)
08.03.23	Neurocrine Biosciences to Participate at Investor Conferences in March (PR Newswire)
03.03.23	Neurocrine Biosciences Presents Data on Improvements Over Time with Long-Term Use of INGREZZA® (valbenazine) Capsules in Older and Elderly Patients at the American Association for Geriatric Psychi... (PR Newswire)
07.02.23	Neurocrine Biosciences to Present at the SVB Securities Global Biopharma Conference (PR Newswire)
06.02.23	Neurocrine Biosciences Inc Q4 Earnings Summary (RTTNews)
06.02.23	Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023 (PR Newswire)
17.01.23	Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2022 Financial Results (PR Newswire)
09.01.23	Neurocrine, Voyager To Advance Multiple Gene Therapies For Neurological Diseases Treatment (RTTNews)
03.01.23	Neurocrine Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference (PR Newswire)
22.12.22	Neurocrine Biosciences Announces U.S. FDA Accepts Supplemental New Drug Application for Valbenazine as a Treatment for Chorea Associated with Huntington Disease (PR Newswire)
06.12.22	Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-827104 in Pediatric Patients with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep (PR Newswire)
02.12.22	Neurocrine Biosciences Presents Demographic and Clinical Characteristics Data of Pediatric Patients with SCN8A-Related Epilepsies at AES 2022 (PR Newswire)
08.11.22	Neurocrine Biosciences to Present at Upcoming Healthcare Conferences (PR Newswire)
03.11.22	Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsules at the American Society of Consultant Pharmacists (ASCP) 2022 Annual Meeting (PR Newswire)
03.11.22	Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022 (PR Newswire)
01.11.22	Neurocrine Biosciences Inc Q3 Profit Increases, beats estimates (RTTNews)
01.11.22	Neurocrine Biosciences Reports Third Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance (PR Newswire)
27.10.22	Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia (PR Newswire)
24.10.22	Neurocrine Biosciences Presents Real-World Parkinson's Disease Patient Characteristics From ONGENTYS® (opicapone) Open-Label Study at ANA2022 (PR Newswire)
19.10.22	Neurocrine Biosciences Presents Data on Benztropine Use Among People Treated with Antipsychotics at the 2022 American Psychiatric Nurses Association (APNA) Annual Conference (PR Newswire)
11.10.22	Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2022 Financial Results (PR Newswire)
29.09.22	Neurocrine Biosciences Appoints Dr. Ingrid Delaet as Chief Regulatory Officer (PR Newswire)
19.09.22	Neurocrine Biosciences Presents INGREZZA® (valbenazine) Data on Sustained Treatment Response at Psych Congress 2022 (PR Newswire)
15.09.22	Neurocrine Biosciences to Present Study Findings on Evolving Tardive Dyskinesia Education Needs of Physicians at the 2022 MDS International Congress (PR Newswire)
15.09.22	Neurocrine Biosciences Presents New Post-Hoc Analysis of ONGENTYS® (opicapone) Capsules Effect on COMT Activity at the 2022 MDS International Congress (PR Newswire)
12.09.22	Parkinson & Movement Disorder (PMD) Alliance and Neurocrine Biosciences Announce New Survey Results Revealing the Significant Impact OFF Time Has on People with Parkinson's Disease and Their Care ... (PR Newswire)
06.09.22	Neurocrine Biosciences to Present at the Morgan Stanley 20th Annual Global Healthcare Conference (PR Newswire)
04.08.22	Neurocrine Biosciences Inc Q2 Earnings Summary (RTTNews)
04.08.22	Neurocrine Biosciences Reports Second Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance (PR Newswire)
14.07.22	Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2022 Financial Results (PR Newswire)
13.06.22	Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2022 (PR Newswire)
08.06.22	Neurocrine Biosciences to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference (PR Newswire)
06.06.22	Neurocrine Biosciences Honored at CARES Foundation 22nd Anniversary Gala (PR Newswire)
06.06.22	Neurocrine Biosciences Presents Data on Sleep Disturbances and OFF Time in Patients with Parkinson's Disease and Motor Fluctuations at SLEEP 2022 (PR Newswire)
25.05.22	Neurocrine Biosciences Announces Repurchase of Convertible Notes (PR Newswire)
23.05.22	Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data on Tardive Dyskinesia Improvement and Stability of Psychiatric Symptoms at American Psychiatric Association Annual Meeting 2022 (PR Newswire)
13.05.22	Neurocrine Biosciences Receives Orphan Drug Designation for Valbenazine as a Treatment for Chorea Associated with Huntington Disease (PR Newswire)
04.05.22	Neurocrine Biosciences Inc Q1 Profit Decreases, misses estimates (RTTNews)
04.05.22	Neurocrine Biosciences Reports First Quarter 2022 Financial Results and Reiterates 2022 Financial Guidance (PR Newswire)
03.05.22	Neurocrine Biosciences to Present at the Bank of America Securities 2022 Healthcare Conference (PR Newswire)
02.05.22	Neurocrine Biosciences Honors Mental Health Awareness Month and Fifth Anniversary of Tardive Dyskinesia Awareness Week (PR Newswire)
13.04.22	Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2022 Financial Results (PR Newswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Lonza Grp	534.20	0.60 %	K V
Roche Hldg G	252.40	0.40 %	K V
Nestle	76.06	0.29 %	K V
Swisscom	504.50	0.10 %	K V
Sonova Hldg	304.60	0.00 %	K V
CieFinRichemont	121.50	-0.69 %	K V
Holcim	87.78	-0.72 %	K V
Sika	226.90	-0.74 %	K V
ABB	48.91	-1.27 %	K V
Logitech Intl	70.64	-1.86 %	K V

mehr

20.11.24		Anleger in New York halten sich zurück: NASDAQ Composite in der Verlustzone
30.10.24		Anleger in New York halten sich zurück: NASDAQ Composite gibt zum Handelsende nach
30.10.24		Handel in New York: NASDAQ Composite verbucht Verluste
30.10.24		Gute Stimmung in New York: NASDAQ Composite mittags fester
30.10.24		Mittwochshandel in New York: NASDAQ Composite beginnt Mittwochssitzung in der Gewinnzone
28.08.24		NASDAQ Composite-Handel aktuell: NASDAQ Composite präsentiert sich zum Handelsende leichter
28.08.24		Handel in New York: So performt der NASDAQ Composite am Mittwochnachmittag
28.08.24		Schwache Performance in New York: So steht der NASDAQ Composite aktuell